MX2019015741A - Tratamiento con plasminogeno de afecciones asociadas a la sobreexpresion de pai-1. - Google Patents
Tratamiento con plasminogeno de afecciones asociadas a la sobreexpresion de pai-1.Info
- Publication number
- MX2019015741A MX2019015741A MX2019015741A MX2019015741A MX2019015741A MX 2019015741 A MX2019015741 A MX 2019015741A MX 2019015741 A MX2019015741 A MX 2019015741A MX 2019015741 A MX2019015741 A MX 2019015741A MX 2019015741 A MX2019015741 A MX 2019015741A
- Authority
- MX
- Mexico
- Prior art keywords
- pai
- overexpression
- conditions associated
- level
- plasminogen
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title abstract 3
- 108010051456 Plasminogen Proteins 0.000 title abstract 3
- 230000002018 overexpression Effects 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 abstract 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 1
- 230000003054 hormonal effect Effects 0.000 abstract 1
- 230000001771 impaired effect Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000007838 tissue remodeling Effects 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere al uso del plasminógeno, una variante de este, o un análogo que tiene una actividad de plasminógeno para la prevención o tratamiento de una afección o una enfermedad que se caracteriza con un mayor nivel de PAI-1. Las afecciones y enfermedades que se caracterizan con un mayor nivel de PAI-1 se reagrupan dentro de dos categorías: las enfermedades asociadas a una capacidad alterada de remodelación tisular y vascular, y los trastornos metabólicos y hormonales asociados a un mayor nivel de PAI-1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762523901P | 2017-06-23 | 2017-06-23 | |
| PCT/IB2018/000655 WO2018234861A1 (en) | 2017-06-23 | 2018-06-22 | Plasminogen treatment of conditions associated with pai-1 overexpression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019015741A true MX2019015741A (es) | 2020-11-11 |
Family
ID=64737041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015741A MX2019015741A (es) | 2017-06-23 | 2018-06-22 | Tratamiento con plasminogeno de afecciones asociadas a la sobreexpresion de pai-1. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US11826404B2 (es) |
| EP (1) | EP3641888B1 (es) |
| JP (1) | JP2020524689A (es) |
| KR (1) | KR20200019217A (es) |
| CN (1) | CN110831668B (es) |
| AU (1) | AU2018287316B2 (es) |
| BR (1) | BR112019027229A2 (es) |
| CA (1) | CA3068153A1 (es) |
| CL (1) | CL2019003789A1 (es) |
| DK (1) | DK3641888T3 (es) |
| ES (1) | ES2965937T3 (es) |
| FI (1) | FI3641888T3 (es) |
| IL (1) | IL271470B2 (es) |
| MX (1) | MX2019015741A (es) |
| MY (1) | MY203136A (es) |
| RU (1) | RU2020100080A (es) |
| SG (1) | SG11201912813SA (es) |
| TW (1) | TWI868051B (es) |
| WO (1) | WO2018234861A1 (es) |
| ZA (1) | ZA202000280B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3047175A1 (en) | 2016-12-15 | 2018-06-21 | Talengen International Limited | Method for mitigating heart disease |
| TW201829448A (zh) * | 2016-12-15 | 2018-08-16 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途 |
| CN110114082A (zh) | 2016-12-15 | 2019-08-09 | 泰伦基国际有限公司 | 一种预防和治疗脂肪代谢紊乱及其相关病症的方法 |
| WO2021155867A1 (zh) * | 2020-02-06 | 2021-08-12 | 泰伦基国际有限公司 | 一种预防和治疗多发性硬化症的方法和药物 |
| EP4122488A4 (en) * | 2020-03-24 | 2023-04-05 | Talengen International Limited | METHOD AND MEDICATION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| CA3176934A1 (en) * | 2020-03-24 | 2021-09-30 | Talengen International Limited | Method and drug for treating parkinson's disease |
| CN115666625A (zh) * | 2020-03-24 | 2023-01-31 | 泰伦基国际有限公司 | 一种促进错误折叠蛋白及其聚集物降解的方法和药物 |
| CN112174979B (zh) * | 2020-10-27 | 2021-09-07 | 黑龙江中医药大学 | 一种治疗多囊卵巢综合征的药物及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5520912A (en) * | 1993-07-02 | 1996-05-28 | Immuno Aktiengesellschaft | Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen |
| AU1624801A (en) | 1999-11-19 | 2001-05-30 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| AU3173301A (en) * | 2000-02-11 | 2001-08-20 | European Molecular Biology Laboratory | Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity |
| GB0509438D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
| CA2662083C (en) * | 2006-08-28 | 2016-09-20 | Omnio Healer Ab | Novel drug target of preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health |
| EP2056864B1 (en) * | 2006-08-28 | 2013-12-11 | Omnio Healer AB | Candidates against infection |
| CN112142845A (zh) * | 2013-08-13 | 2020-12-29 | 赛诺菲 | 纤溶酶原激活剂抑制剂-1(pai-1)的抗体及其用途 |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| TW201722464A (zh) * | 2015-11-10 | 2017-07-01 | 波麥堤克生化科學有限公司 | 用於傷口癒合之纖維蛋白溶酶原給藥方案 |
| TW201829448A (zh) * | 2016-12-15 | 2018-08-16 | 大陸商深圳瑞健生命科學硏究院有限公司 | 纖溶酶原在製備預防或治療肥胖症及疾病倂發的肥胖的藥物中的用途 |
| CN110121358A (zh) * | 2016-12-15 | 2019-08-13 | 泰伦基国际有限公司 | 一种预防和治疗肺纤维化的方法 |
| WO2018107700A1 (zh) * | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗病理性肾组织损伤的方法 |
-
2018
- 2018-06-15 TW TW107120839A patent/TWI868051B/zh active
- 2018-06-22 IL IL271470A patent/IL271470B2/en unknown
- 2018-06-22 EP EP18821458.9A patent/EP3641888B1/en active Active
- 2018-06-22 CN CN201880041573.5A patent/CN110831668B/zh active Active
- 2018-06-22 JP JP2019570806A patent/JP2020524689A/ja active Pending
- 2018-06-22 ES ES18821458T patent/ES2965937T3/es active Active
- 2018-06-22 DK DK18821458.9T patent/DK3641888T3/da active
- 2018-06-22 AU AU2018287316A patent/AU2018287316B2/en active Active
- 2018-06-22 MY MYPI2019007619A patent/MY203136A/en unknown
- 2018-06-22 KR KR1020207001617A patent/KR20200019217A/ko not_active Ceased
- 2018-06-22 WO PCT/IB2018/000655 patent/WO2018234861A1/en not_active Ceased
- 2018-06-22 FI FIEP18821458.9T patent/FI3641888T3/fi active
- 2018-06-22 SG SG11201912813SA patent/SG11201912813SA/en unknown
- 2018-06-22 CA CA3068153A patent/CA3068153A1/en active Pending
- 2018-06-22 MX MX2019015741A patent/MX2019015741A/es unknown
- 2018-06-22 RU RU2020100080A patent/RU2020100080A/ru unknown
- 2018-06-22 BR BR112019027229-1A patent/BR112019027229A2/pt not_active Application Discontinuation
- 2018-06-22 US US16/625,335 patent/US11826404B2/en active Active
-
2019
- 2019-12-20 CL CL2019003789A patent/CL2019003789A1/es unknown
-
2020
- 2020-01-15 ZA ZA2020/00280A patent/ZA202000280B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI3641888T3 (fi) | 2023-12-19 |
| IL271470B1 (en) | 2025-03-01 |
| DK3641888T3 (da) | 2024-01-02 |
| CN110831668A (zh) | 2020-02-21 |
| EP3641888A1 (en) | 2020-04-29 |
| US11826404B2 (en) | 2023-11-28 |
| EP3641888B1 (en) | 2023-10-11 |
| US20210330761A1 (en) | 2021-10-28 |
| SG11201912813SA (en) | 2020-01-30 |
| JP2020524689A (ja) | 2020-08-20 |
| RU2020100080A (ru) | 2021-07-23 |
| TW201904990A (zh) | 2019-02-01 |
| CN110831668B (zh) | 2024-04-12 |
| IL271470A (en) | 2020-01-30 |
| RU2020100080A3 (es) | 2021-11-02 |
| EP3641888A4 (en) | 2021-03-10 |
| ES2965937T3 (es) | 2024-04-17 |
| KR20200019217A (ko) | 2020-02-21 |
| IL271470B2 (en) | 2025-07-01 |
| ZA202000280B (en) | 2021-08-25 |
| BR112019027229A2 (pt) | 2020-07-07 |
| WO2018234861A1 (en) | 2018-12-27 |
| AU2018287316A1 (en) | 2020-02-06 |
| MY203136A (en) | 2024-06-10 |
| TWI868051B (zh) | 2025-01-01 |
| CL2019003789A1 (es) | 2020-07-10 |
| AU2018287316B2 (en) | 2024-09-19 |
| CA3068153A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019015741A (es) | Tratamiento con plasminogeno de afecciones asociadas a la sobreexpresion de pai-1. | |
| IL286636A (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES OR DISORDERS RELATED TO KRAS | |
| MX2020001774A (es) | Composiciones y métodos para tratar enfermedad colestásica. | |
| IL276383B1 (en) | Treatment of ophthalmological diseases | |
| IL273169A (en) | A new combination of active substances for the treatment of advanced interstitial and lymphoid lung diseases | |
| MX2017016134A (es) | Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad. | |
| SG11202111168UA (en) | Compositions and methods for improving skin health and for the treatment and prevention of diseases, disorders and conditions associated with pathogenic microbes | |
| MX2021007260A (es) | Inhibidores de la vía de cinasa janus 1 (jak1) para el tratamiento de enfermedades gastrointestinales. | |
| MX2018005588A (es) | Terapia de sustitucion de plasminogeno para la deficiencia de plasminogeno. | |
| IL289405A (en) | Personalized treatment of eye diseases | |
| ZA201804696B (en) | Therapeutic use of inhibitors of t cell activation or stimulation | |
| WO2016055797A3 (en) | Valproic acid for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation | |
| EP3606570B8 (en) | Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds | |
| WO2019165158A8 (en) | Il-6 inhibitors and methods of treatment | |
| WO2018208793A8 (en) | S-NITROSOGLUTATHIOME INHIBITORS (GSNO) AND GSNO REDUCTASE USEFUL IN THERAPY | |
| PH12020551179A1 (en) | Methods for treating mitochondrial disorder | |
| EP4295906A3 (en) | Treatment of restenosis using temsirolimus | |
| SG11202010034WA (en) | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRß ANTIBODY | |
| MX2020000118A (es) | Composiciones y metodos para mejorar la funcion cardiaca. | |
| ZA202105101B (en) | Peptides for treatment and prevention of diabetes and associated disorders | |
| PH12019502388A1 (en) | Prevention and/or treatment of inflammatory skin disease | |
| SG10201907677QA (en) | Formulations for use in the prevention and/or treatment of peripheral neuropathy and its associated diseases. | |
| PH12019501820A1 (en) | Pharmaceutical compositions for combination therapy | |
| MX2021012098A (es) | Oligonucleotidos antisentido del transcrito tipo 2 de angiopoyetina (angptl2) y sus usos. | |
| SG11202104958UA (en) | Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases |